Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Liabilities and Shareholders Equity (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Liabilities and Shareholders Equity for 15 consecutive years, with $56.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 1.59% to $56.0 million in Q4 2025 year-over-year; TTM through Oct 2025 was $200.1 million, a 22.01% decrease, with the full-year FY2025 number at $55.2 million, down 7.91% from a year prior.
  • Liabilities and Shareholders Equity was $56.0 million for Q4 2025 at PharmaCyte Biotech, up from $45.1 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $92.3 million in Q4 2021 to a low of $6.6 million in Q3 2021.
  • A 5-year average of $61.7 million and a median of $70.8 million in 2024 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 1216.56% in 2022, then plummeted 38.58% in 2025.
  • PharmaCyte Biotech's Liabilities and Shareholders Equity stood at $92.3 million in 2021, then dropped by 10.79% to $82.3 million in 2022, then fell by 4.21% to $78.9 million in 2023, then tumbled by 30.15% to $55.1 million in 2024, then rose by 1.59% to $56.0 million in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Liabilities and Shareholders Equity are $56.0 million (Q4 2025), $45.1 million (Q3 2025), and $55.2 million (Q2 2025).